Importantly, giving us your very valuable medical data will provide almost zero additional value to you but the responses the suicide machine provides will be betterish ± a 50% confidence interval.

Which is not to justify it at all, but idle hands and all that... money definitely enables a lot of problematic behaviour.

I have had the displeasure of working with some 'high net-worth' individuals over the last decade and it is remarkable how little work they actually do after a certain point. Phil probably writes for 3-4 hours a day on average and then he has a whole 12 hour day to kill.

This is classic product management metric chasing. Everything is sacrificed to get your annual bonus because things like brand value and moral goods don’t have metrics attached. Accelerating towards the cliff.

It has both Zach de la Rocha and Billy Corgan in it for some reason, releases a single EP and then collapses like a supermassive star.

Along the way we’ll have to overthrow the last 70+ years of obesity stigma and frankly sexism about weight. It‘s a prejudice people fall back on ad hominem like homophobia.

I genuinely think everyone in the Western world will be taking very small doses of GLP-1s like retatrutide in the next twenty years for the overall metabolic benefits + dopamine satiation + alzheimers prevention. 3rd gen drugs seem to remove a lot of the problems with muscle depletion.

Pretty sure Trump could kidnap Albo to ensure continuity of service at Pine Gap and Albo would respond: “understandable, please continue.”

The U.S. is functionally now a pariah state and must be treated as such until the cancer rotting out the heart of the White House is cut out.

I believe their funding model is decentralised too, so the cost ends up on a lot of smaller books, not the national budget. Between those two things I can see the NHS being able to approve broader use without too much stress.

Yeah, I am not super familiar with the UK regulatory space but it seems to be less conservative than Australia’s in a lot of ways, even in terms of what is generally permissible. They also had a very odd GLP-1 market for a long time where Novo in particular sold doses much cheaper than globally.

PBS managers don‘t want cost blowouts and Novo wouldn‘t be able to handle the spike in demand anyway. I suspect this will be a test balloon to slowly cover other use cases. I don’t know that Semaglutide coming off patent next year would even move the dial much.

Was about what I was expecting, just cardio events is very limited scope but is the easiest to “prove”. I don‘t think preventative doses will ever get approved. Current demographics suggest it would cost more than $50B if everyone who could benefit from GLP-1s took them.

Didn‘t we do this episode 7 years ago when Alexa was supposed to eat everything?

Cue the wealthy deliberately losing teeth as a status symbol or something I guess? Who knows where the winds of class differentiation will blow.